Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense.
What: Shares of Cubist Pharmaceuticals (NASDAQ: CBST.DL ) popped 3% today after Mizuho Securities upgraded the biotechnology company from "neutral" to "buy."
So what: Along with the upgrade, analyst Mario Corso raised his price target on the stock to $77 (from $50), representing about 54% worth of upside to yesterday's close. While bargain hunters might be turned off by the stock's red-hot run in 2013, Corso's valuation work -- which now includes Cubist's pending acquisitions of Optimer Pharmaceuticals and Trius Therapeutics -- suggests that the risk/reward trade-off is still very appealing.
Now what: Using a discounted cash flow model, Mizuho valued Cubist at $77, $96, and $51 in three different revenue/EPS scenarios.
"Catalysts for achieving our price target are the transactions closing/integration by year end 2013, CBST financial guidance in early 2014, CXA-201 Phase III data by year end, and FDA approval of tedizolid toward mid-2014," Mizuho noted.
With Cubist shares up about 65% from its 52-week lows, and trading at a forward P/E of 34, however, I'd wait for a wider margin of safety before betting on those catalysts.
More reliable ways to build wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.